GenScript Biotech Reports First Half 2021 Results
* In the first half of 2021, the Group reported a revenue of approximately USD 229.6 million, a 38.0% YoY increase, and a gross profit of USD 138.6 million , achieving a 28.1% YoY growth. All four of the Group's business segments demonstrated steady growth. * Building on early strategic invest...
Genscript Biotech Reports 2021 Interim Financial Results
Strong Momentum across All Business Segments, particularly in Gene & Cell Therapy CDMO Continue to accelerate R&D investment to capture Future Growth * Revenue of the Group for the six months ended June 30, 2021 was approximately US$229.6 million, representing an increase of 38.0% as compared...
GenScript Joins Forces with Allozymes by Providing Smart Libraries Construction for Precision Protein Engineering
SINGAPORE, Aug. 3, 2021 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK) today announced a collaboration with Allozymes, a synthetic biology company transforming ingredient manufacturing by unlocking protein engineering potential through groundbreaking technologies. In this par...
GenScript Announces Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Kit
PISCATAWAY, N.J., July 28, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance...
GenScript to Host Gene & Cell Engineering Virtual Summit
PISCATAWAY, N.J. , July 13, 2021 /PRNewswire/ -- GenScript®
GenScript receives "Best Contract Development and Manufacturing Organization Award" in the Korea Bioprocessing Excellence Awards 2021
SINGAPORE, June 25, 2021 /PRNewswire/ -- GenScript receives the "Best Contract
Development and Manufacturing Organization Award" on the Korea Bioprocessing
Excellence Awards 2021 held on 24th June 2021. GenScript achieve the Best CDMO
award for two years in a row.
Duke-NUS and GenScript Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test
PISCATAWAY, N.J. and SINGAPORE, June 21, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, and Duke-NUS Medical School, a premier, research intensive medical school, annou...
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb®...
GenScript Launches Research-Grade Lentiviral Vector Packaging Service
PISCATAWAY, N.J., April 28, 2021 /PRNewswire/ -- GenScript®
GenScript ProBio Enters Collaboration with Singapore's Experimental Drug Development Centre to Develop Anti-Fibrosis Therapeutic Antibody Programme
SINGAPORE, April 21, 2021 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK)'s biopharmaceutical CDMO segment, GenScript ProBio announced a collaboration with the Experimental Drug Development Centre (EDDC),Singapore's national platform for drug discovery and development, on an a...
GenScript, Parkway Laboratories and Diagnostics Development (DxD) Hub collaborate to provide cPass(TM) SARS-CoV-2 Neutralizing Antibody Testing Service in Singapore
SINGAPORE, April 12, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), Parkway Laboratories and the Diagnostics Development (DxD) Hub announced their collaboration to provide the cPass™ SARS-CoV-2 neutralizing antibody test inSingapore through Parkway's pane...
GenScript Biotech Reports Full Year 2020 Financial Results
NANJING, China, Mar. 30, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548.HK) today held its 2020 Annual Results Conference, announcing its business updates and financial performance. The Group earned a USD 390 million revenue, representing a 42.9% YoY growth, and aUSD 260 million ...
GenScript Biotech Reports Full Year 2020 Financial Results and Business Results
* Reported a revenue of approximately USD 390 million, a 42.9% YoY increase, and a gross profit ofUSD 260 million, achieving YoY growth of 41.9%. * The Group's non-cell therapy business witnessed its fastest growth in five years with a net profit increase of more than 100%; while its cell ther...
Genscript Biotech Reports Full Year 2020 Financial Results
Highlights: * Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximatelyUS$273.4 million for the year ended December 31, 2019 * Gross profit of the Group for the year ended December 31, 2...
GenScript Signs a Strategic Partnership with the Theragen Etex and MedPACTO for Therapeutic Antibody Drug development
SINGAPORE, March 25, 2021 /PRNewswire/ -- A global leading biotech company GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) announced that the Company has entered into a strategic partnership with the Theragen Etex, a South Korea-based comprehensive pharmaceutical and biotechnology...
GenScript receives "Best Contract Research Organization Award" in the 4th Annual Asia-Pacific Bioprocessing Excellence Awards Ceremony 2021
SINGAPORE, March 16, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the "Best Contract Research Organization Award" on the 4th Annual Asia Pacific Bioprocessing Excellence Awards Ceremony 2021held on 16th March 2021. The award follows GenScri...
GenScript Submits Application with FDA for Use of cPass™ SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening
PISCATAWAY, N.J., Jan. 13, 2021 /PRNewswire/ -- GenScript USA Inc., the world's leading research reagent provider, announced today that it has submitted an application to the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 N...
GenScript and InnoBation Enter into the Agreement for CAR-T therapy
NANJING, China and SEOUL, South Korea, Dec. 15, 2020 /PRNewswire/ -- A global leading biotech company GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) announces that it has reached the agreement for cell line development and engineering, manufacture service of GMP Plasmids and Len...
cPass(TM) SARS-CoV-2 Neutralization Antibody kit is the first EUA authorized test that detects neutralizing antibodies within one hour
SINGAPORE, Nov. 11, 2020 /PRNewswire/ -- Following GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK)'s cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit has received provisional authorization by Health Science Authority (HSA)Singapore on 8th May 2020, CE-IVD marking in Europ...
cPass(TM) SARS-CoV-2 Neutralization Antibody kit is the first EUA authorized test that detects neutralizing antibodies within one hour
SINGAPORE, Nov. 11, 2020 /PRNewswire/ -- Following GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK)'s cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit has received provisional authorization by Health Science Authority (HSA)Singapore on 8th May 2020, CE-IVD marking in Europ...
